Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
siCoV/KK46 in Healthy Volunteers
NCT05208996Phase 1Completed
- Start
- Jan 2021
- Primary completion
- Mar 2021
- Countries
- 1
01
Overview
Phase 1, open-label trial of Mir-19 in coronavirus disease 2019 (COVID-19) (3 cohorts). Primary endpoints: Safety and Tolerability of siCoV/KK46 at 72 hours, Vital Signs at 72 hours and 20 more. Started Jan 2021; status: completed.
02
Drugs
Mir-19
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05208996.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05208996.